evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. the company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. in addition, evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. the company's headquarters are located in rehovot, israel and is listed for trading on the tel aviv stock exchange (tase: evgn) and on the new york stock exch
Company profile
Ticker
EVGN
Exchange
Website
CEO
Ofer Haviv
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
EVGN stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
29 May 24
6-K
Biomica Presents Positive Clinical Data Update from
23 May 24
6-K
Evogene Reports First Quarter 2024 Financial Results
23 May 24
6-K
Current report (foreign)
30 Apr 24
6-K
Current report (foreign)
2 Apr 24
EFFECT
Notice of effectiveness
29 Mar 24
424B5
Prospectus supplement for primary offering
28 Mar 24
6-K
Current report (foreign)
28 Mar 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
20 Mar 24
Transcripts
EVGN
Earnings call transcript
2024 Q1
23 May 24
EVGN
Earnings call transcript
2023 Q4
7 Mar 24
EVGN
Earnings call transcript
2023 Q3
15 Nov 23
EVGN
Earnings call transcript
2023 Q2
17 Aug 23
EVGN
Earnings call transcript
2023 Q1
18 May 23
EVGN
Earnings call transcript
2022 Q3
17 Nov 22
EVGN
Earnings call transcript
2022 Q2
31 Aug 22
EVGN
Earnings call transcript
2022 Q1
27 May 22
EVGN
Earnings call transcript
2021 Q4
10 Mar 22
EVGN
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
SC 13G
SILVERARC CAPITAL MANAGEMENT, LLC
14 Feb 24
SC 13G/A
MACQUARIE GROUP LTD
11 Feb 22
SC 13G/A
ARK Investment Management LLC
9 Feb 22
SC 13G/A
ARK Investment Management LLC
16 Feb 21
SC 13G/A
Senvest Management, LLC
12 Feb 21
SC 13G/A
WADDELL & REED FINANCIAL INC
12 Feb 21
SC 13G/A
UBS Group AG
8 Feb 21
SC 13G/A
ALPHA CAPITAL ANSTALT
21 Jan 21
SC 13G/A
ALPHA CAPITAL ANSTALT
2 Nov 20
SC 13G
ARK Investment Management LLC
9 Oct 20
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
2.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 32 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 8.40 mm |
Total shares | 1.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Alpha Capital Anstalt | 1.04 mm | $0.00 |
SNS Financial | 10.00 k | $8.40 mm |
Cutler | 2.60 k | $2.00 k |
News
Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'
7 Mar 24
Evogene Q4 EPS $(0.13) Beats $(0.14) Estimate, Sales $578.00K Beat $500.00K Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
Evogene Earnings Preview
6 Mar 24
Casterra Announced New Agreements With Seed Producers in Brazil And Africa To Meet Growing Demand ForIts Elite Castor Seed Varieties
5 Mar 24
Press releases
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
23 May 24
Evogene Reports First Quarter 2024 Financial Results
23 May 24
Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds
21 May 24
Evogene Schedules First Quarter 2024 Financial Results Release
9 May 24
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
16 Apr 24